error fb Gplus IN twitter down-arrow Email Phone Check-Mark padlock circle_arrow minus plus play_btn close Clipboard_Icon Shopping-Cart_Icon Speech_Bubble_Icon Stethoscope_Icon pharmacists menu left-arrow right-arrow facebook search cart

Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System

Who Can Benefit from CGM?

Many of your patients struggle to maintain good glycemic control, despite their best intentions. Whether your patient has type 1 or type 2 diabetes, or they are being treated with an insulin injection regimen or pump therapy – they may benefit from CGM.

Who Can Benefit from CGM?

  • Uncontrolled type 1 and type 2 diabetes
  • On insulin injections or insulin pump therapy
  • Hypoglycemia unawareness
  • At or above A1C goal

We offer two CGM options for your patients

Personal CGM

The Dexcom G5® Mobile CGM System, our most current CGM patient platform, is approved for patients 2 years and older. This fully mobile System gives patients the ability to view their glucose data directly on a compatible mobile device.*

Professional CGM

The Dexcom G4® PLATINUM Professional CGM System is practice-owned and gives you real-time feedback and insights about your patient’s glycemic control, which can inform therapeutic treatment recommendations. The System can be blinded when clinically necessary.

Lower A1C in CGM Users

CGM can benefit all patients taking insulin – whether they’re taking multiple daily insulin injections or using a pump.

Support and Education

Dexcom will be your trusted partner in bringing CGM to your practice and patients. We assist with patient onboarding, including verification of insurance coverage, as well as provide clinician and patient training and education about CGM and the Dexcom products.

More information

For more information, or to get started with adding CGM to your practice, click one of the links below to be contacted by a Dexcom representative.

AACE/ACE Consensus: Glucose Monitoring, Endocr Pract. 2015;21(No. 5) 523-530.

JDRF Continuous Glucose Monitoring Study Group. N Engl J Med. 2008;359(14):1464-1476.

* To view a list of compatible devices, visit

LBL014047 Rev 001